Pipeline
Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics.
Indication
Product Candidate
Discovery
Ind enabling phase
Phase 1
Retinitis Pigmentosa
Genotype agnostic
RTx-015
Pre-IND
Other Inherited retinal degenerations
Choroideremia
Stargardt’s disease
RTx-015
Discovery
Geographic Atrophy
RTX-021
Discovery